The acquisition significantly strengthens Neurocrine's portfolio in endocrinology and rare diseases with a first-in-class therapy that has demonstrated strong commercial traction. The $92 million in Q4 2025 revenue suggests accelerating adoption of VYKATTM XR, which could drive substantial revenue growth post-acquisition. Traders should monitor integration progress and potential synergies, as well as any regulatory developments that could impact the expected 90-day closing timeline.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Apr 6 $52.25entry
- T+1 · 7mo ago +0.19%α +0.13% · $52.35
- T+5 · 7mo ago +0.75%α −3.39% · $52.64
- T+20 · 7mo ago +1.24%α −7.74% · $52.90
- T+60 · due 5mo ago Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion. The acquisition includes Soleno's FDA-approved treatment VYKATTM XR for Prader-Willi syndrome, which generated $190 million in 2025 revenue. The deal is expected to close within 90 days, subject to regulatory approvals and other customary conditions.
Key Financial Metrics
Key Facts
- Neurocrine Biosciences will acquire Soleno Therapeutics for $53.00 per share in cash
- Total transaction equity value is $2.9 billion
- VYKATTM XR generated $190 million in 2025 revenue, including $92 million in Q4 2025
- The deal represents a 34% premium to Soleno's closing price on April 2, 2026
- The acquisition is expected to close within 90 days of announcement
- The transaction is funded with cash on hand and modest pre-payable debt
Financial Impact
Total equity value of $2.9 billion with $53.00 per share cash payment
Risk Factors
- Regulatory approval delays
- Integration challenges between the two companies
- Potential competition from alternative treatments for Prader-Willi syndrome
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-142911 |
| Document: d142985dex101.htm | 0001193125-26-142911 |
| Document: d142985d8k.htm | 0001193125-26-142911 |
| Document: d142985dex991.htm | 0001193125-26-142911 |
| Document: 0001193125-26-142911-index-headers.html | 0001193125-26-142911 |
| Document: 0001193125-26-142911-index.html | 0001193125-26-142911 |
| Document: 0001193125-26-142911.txt | 0001193125-26-142911 |
Track record
10 reports on SLNO
The track record builds as more bullish or bearish reports settle.
Filters
- Jun 11, 202622w ago Institutional Cluster Bullish 6/10 No price data
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 No price data
- May 28, 202624w ago 15-12G Bearish 8/10 No price data
- May 28, 202624w ago EFFECT Bearish 5/10 No price data
- May 18, 202626w ago 8-K / 25-NSE Bullish 8/10 Entry $53.01 No price data
- Apr 7, 202631w ago 8-K Bearish 7/10 Entry $52.35 to $52.62 ▼ −0.52% +4.81% vs SPY
- Apr 6, 202632w ago 8-K Bullish 8/10 Viewing Entry $52.25 to $52.64 ▲ +0.75% −3.39% vs SPY
- Mar 27, 202633w ago Insider Cluster Neutral 3/10 Entry $30.05 to $52.25 ▲ +73.88% +70.01% vs SPY
- Feb 26, 202637w ago 8-K Bullish 8/10 Entry $38.09 to $38.57 ▲ +1.26% +2.42% vs SPY
- Feb 26, 202637w ago 8-K Neutral 3/10 Entry $38.09 to $38.57 ▲ +1.26% +2.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers